Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, and C797S resistance mutations in September 2024 ...

Black Diamond Therapeutics, Inc. ( (BDTX) ) has released its Q3 earnings. Here is a breakdown of the information Black Diamond Therapeutics, ...

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest ...

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Black Diamond Therapeutics (BDTX – Research Report), retaining the ...

Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Black Diamond ...

CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of ...

Detailed price information for Black Diamond Therapeutics Inc (BDTX-Q) from The Globe and Mail including charting and trades.